Denali Therapeutics Inc. (DNLI) Stock Score, Valuation & Financial Research

Denali Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DNLI

Denali Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 19.28. These figures are a research snapshot, not a buy or sell recommendation.

What Denali Therapeutics Inc. does

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Denali Therapeutics is a clinical-stage biopharmaceutical company that generates revenue primarily through collaboration and license agreements with pharmaceutical partners. The company receives upfront payments, research and development funding, and is eligible for milestone payments and future royalties upon the successful development and commercialization of its therapeutic candidates.

Products and services

  • Denali develops a portfolio of product candidates for neurodegenerative diseases, including enzyme replacement therapies using its Transport Vehicle (TV) platform to cross the blood-brain barrier, and small molecule inhibitors such as BIIB122/DNL151 for Parkinson's disease.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Biogen Inc. — Collaboration for the development and potential co-commercialization of BIIB122/DNL151 for Parkinson's disease. Source

Competitors and product-market comparisons

  • Biogen Inc. — While a partner, Biogen also operates in the neurodegenerative disease space and competes in the development of therapies for Parkinson's and other CNS disorders. Source

Business strengths to evaluate

  • Proprietary Transport Vehicle (TV) platform technology Source
  • Deep expertise in blood-brain barrier biology Source

Business risks and research considerations

  • Dependence on third-party collaborators and contract manufacturers Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DNLI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 19.28
Market capitalization:
3.06B (currency not supplied)
Revenue:
USD 3.6M
Net income:
USD -511.45M
Free cash flow:
USD -422.1M
Cash:
USD 201.53M
Total debt:
USD 27.51M
EPS:
USD -2.84

What stands out

  • Free cash flow is USD -422.1M, negative for the stored period.
  • The balance sheet shows USD 201.53M of cash versus USD 27.51M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 174.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DNLI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DNLI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DNLI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DNLI to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of DNLI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DNLI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.